Primary regulatory
FDA approves Zepbound for obstructive sleep apnea in adults with obesity
FDA approval announcement adding moderate-to-severe obstructive sleep apnea in adults with obesity to Zepbound's indications.
U.S. Food and Drug AdministrationPublished 2024-12-20Accessed 2026-07-12
Registry record
Source metadata
- Publisher
- U.S. Food and Drug Administration
- Source type
- Primary regulatory
- Registry ID
fda-zepbound-osa-approval-2024
Source usage
Linked from 2 pages
Interpretation boundary
What this record can and cannot establish
Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.